END-SANS

The END-SANS project from HUNOR tests a novel, solid nanostructured drug formula that can be used inophthalmic inserts to treat Spaceflight-Associated Neuro-ocular Syndrome (SANS). The project has two aims. Firstly, it plans to study the impact of microgravity on eye insert materials containing Active Pharmaceutical Ingredients (API). Inserts with API will launch passively and return for further stability analyses. Secondly, one crew member will use the eye inserts without the API once daily for at least five days and complete a questionnaire about their experience using the insert. Pre- and post-clinical testing will also be carried out to assess ocular health and monitor biological effects. Results will show whether nanofibrous drug carriers may offer a promising and innovative approach for stable and precise treatments in ophthalmic applications, which are also relevant to terrestrial applications such as macular edema.